http://orcid.org/0000-0003-1974-7844
References
- Eaton WW, Rose NR, Kalaydjian A, et al. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007;29(1):1–9.
- Nixon CP, Sweeney JD. Autoimmune cytopenias: diagnosis & management. R I Med J. 2016;99(12):36–40.
- Zinzani PL. The many faces of marginal zone lymphoma. ASH Educ Program Book. 2012;2012(1):426–432.
- Dasanu CA, Bockorny B, Grabska J, et al. Prevalence and pattern of autoimmune conditions in patients with marginal zone lymphoma: a single institution experience. Conn Med. 2015;79(4):197–200.
- Behdad A, Bailey NG. Diagnosis of splenic B-cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings. Arch Pathol Lab Med. 2014;138(10):1295–1301.
- Parry M, Rose-Zerilli MJ, Ljungström V, et al. Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(18):4174–4183.
- Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69:258–271. [cited 2018 Jun 22]. Wiley Online Library. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.10062
- Salama A. Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review. Transfus Med Hemotherapy. 2015;42(5):294–301.
- TS dos S, Tavares RS, Farias DLCD. Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges. Rev Bras Hematol E Hemoter. 2017;39(2):146–154.
- Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30(1–2):139–148.
- Fodor A, Molnar MZ, Krenacs L, et al. Autoimmune hemolytic anemia as a risk factor of poor outcome in patients with splenic marginal zone lymphoma. Pathol Oncol Res POR. 2009;15(4):597–603.